AR066103A1 - Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR066103A1 AR066103A1 ARP080101597A ARP080101597A AR066103A1 AR 066103 A1 AR066103 A1 AR 066103A1 AR P080101597 A ARP080101597 A AR P080101597A AR P080101597 A ARP080101597 A AR P080101597A AR 066103 A1 AR066103 A1 AR 066103A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- cycloalkyl
- alkyl
- hydrogen atom
- groups
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
Abstract
Aplicacion en terapéutica para prevenir o tratar dolores, vértigo, náuseas, vomitos, dislipidemia, patologías neurologicas, psiquiátricas, neurodegenerativas, infecciones, epilepsia entre otros. Medicamentos y composicion farmacéutica. Reivindicacion 1: Compuesto que responde a la formula (1) en a que: X representa un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, un grupo S(O)mRö, hidroxi o ciano, A está ausente o bien representaun enlace, un átomo de oxígeno, un átomo de azufre, un grupo NR, C(O)NR', SO2NR', un grupo alquileno C1-2, o un grupo alquenilo C2, R1 y R2 representan, independientemente el uno del otro, uno o varios grupos elegidos entre un átomo de hidrogeno, ungrupo alquilo C1-6, un grupo alcoxi C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, un grupo cicloalquilo C3-7-alcoxi C1-6, un átomo de halogeno, un grupo ciano, C(O)R' C(O)OR', C(O)NR10R20, NO2, un grupo NR10R20, NR10C(O)-R20, estandosustituidos opcionalmente los grupos alquilo C1-6 y alcoxi C1-6 con uno o varios átomos o grupos elegidos independientemente los unos de los otros entre los átomos de halogeno, los grupos hidroxi, amino, NR10R20, R representa un grupo elegido entreun átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-aIquilo C1-6, C(O)R', SO2Rö, CO2Rö, C(O)NR10R20, R' representa un grupo elegido entre un átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-6, Rö representa un grupo elegido entre un grupo aIquiIo C1-6, cicloalquilo C3-7, cicloalquiIo C3-7-alquilo C1-6; R10 y R20 representan, independientemente el uno del otro, uno o varios grupos elegidos entre un átomo de hidrogeno, ungrupo alquilo C1-6, cicloaIquilo C3-7, cicloalquilo C3-7-alquilo C1-6 o bien R10 y R20 pueden formar un ciclo saturado o parcialmente insaturado, que contiene de 5 a 7 átomos de carbono y que contiene opcionalmente un heteroátomo elegido entre O, No S(O)m, m representa 0, 1 o 2, en el estado de base o de sal de adicion a un ácido, así como en el estado de hidrato o de solvato. Reivindicacion 9: Compuesto de formula (4) en la que X es tal como se ha definido en la formula general (1) segun lareivindicacion 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0702807A FR2915197B1 (fr) | 2007-04-18 | 2007-04-18 | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066103A1 true AR066103A1 (es) | 2009-07-22 |
Family
ID=38739381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101597A AR066103A1 (es) | 2007-04-18 | 2008-04-18 | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7868007B2 (es) |
| EP (1) | EP2146991B1 (es) |
| JP (1) | JP2010524907A (es) |
| KR (1) | KR20090130060A (es) |
| CN (1) | CN101657451A (es) |
| AR (1) | AR066103A1 (es) |
| AT (1) | ATE475661T1 (es) |
| AU (1) | AU2008257323A1 (es) |
| BR (1) | BRPI0810430A2 (es) |
| CA (1) | CA2683933A1 (es) |
| CY (1) | CY1111601T1 (es) |
| DE (1) | DE602008001981D1 (es) |
| DK (1) | DK2146991T3 (es) |
| ES (1) | ES2348969T3 (es) |
| FR (1) | FR2915197B1 (es) |
| HR (1) | HRP20100573T1 (es) |
| IL (1) | IL201416A0 (es) |
| MX (1) | MX2009011215A (es) |
| PL (1) | PL2146991T3 (es) |
| PT (1) | PT2146991E (es) |
| RS (1) | RS51462B (es) |
| RU (1) | RU2009142430A (es) |
| SI (1) | SI2146991T1 (es) |
| TW (1) | TW200906401A (es) |
| UY (1) | UY31036A1 (es) |
| WO (1) | WO2008145842A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5576874B2 (ja) * | 2008-11-14 | 2014-08-20 | ザ スクリプス リサーチ インスティテュート | モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物 |
| EP2382012A2 (en) * | 2008-12-24 | 2011-11-02 | Bial-Portela & CA, S.A. | Pharmaceutical compounds |
| AR076381A1 (es) | 2009-04-22 | 2011-06-08 | Janssen Pharmaceutica Nv | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa |
| US8450350B2 (en) * | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| WO2012030907A1 (en) * | 2010-09-03 | 2012-03-08 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
| KR20140001206A (ko) | 2010-09-27 | 2014-01-06 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 옥소피페라진-아제티딘 아미드 및 옥소다이아제핀-아제티딘 아미드 |
| RU2013123274A (ru) | 2010-10-22 | 2014-11-27 | Янссен Фармацевтика Нв | Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR112020025642A2 (pt) * | 2018-08-13 | 2021-03-23 | F. Hoffmann-La Roche Ag | compostos heterocíclicos como inibidores da monoacilglicerol lipase |
| RS65912B1 (sr) | 2018-08-13 | 2024-10-31 | Hoffmann La Roche | Nova heterociklična jedinjenja kao inhibitori monoacilglicerol lipaze |
| CN113164458B (zh) | 2018-09-28 | 2024-09-13 | 詹森药业有限公司 | 单酰基甘油脂肪酶调节剂 |
| JP7697934B2 (ja) | 2019-09-30 | 2025-06-24 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射線標識されたｍｇｌ ｐｅｔリガンド |
| WO2023130023A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| DE102004005172A1 (de) * | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
-
2007
- 2007-04-18 FR FR0702807A patent/FR2915197B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-16 BR BRPI0810430-1A2A patent/BRPI0810430A2/pt not_active IP Right Cessation
- 2008-04-16 EP EP08787964A patent/EP2146991B1/fr active Active
- 2008-04-16 JP JP2010503550A patent/JP2010524907A/ja active Pending
- 2008-04-16 DE DE602008001981T patent/DE602008001981D1/de active Active
- 2008-04-16 KR KR1020097021600A patent/KR20090130060A/ko not_active Withdrawn
- 2008-04-16 RS RSP-2010/0434A patent/RS51462B/sr unknown
- 2008-04-16 RU RU2009142430/04A patent/RU2009142430A/ru not_active Application Discontinuation
- 2008-04-16 AU AU2008257323A patent/AU2008257323A1/en not_active Abandoned
- 2008-04-16 MX MX2009011215A patent/MX2009011215A/es active IP Right Grant
- 2008-04-16 HR HR20100573T patent/HRP20100573T1/hr unknown
- 2008-04-16 CN CN200880012319A patent/CN101657451A/zh active Pending
- 2008-04-16 ES ES08787964T patent/ES2348969T3/es active Active
- 2008-04-16 PL PL08787964T patent/PL2146991T3/pl unknown
- 2008-04-16 PT PT08787964T patent/PT2146991E/pt unknown
- 2008-04-16 CA CA002683933A patent/CA2683933A1/fr not_active Abandoned
- 2008-04-16 SI SI200830079T patent/SI2146991T1/sl unknown
- 2008-04-16 WO PCT/FR2008/000535 patent/WO2008145842A2/fr not_active Ceased
- 2008-04-16 AT AT08787964T patent/ATE475661T1/de active
- 2008-04-16 DK DK08787964.9T patent/DK2146991T3/da active
- 2008-04-17 TW TW097114016A patent/TW200906401A/zh unknown
- 2008-04-18 AR ARP080101597A patent/AR066103A1/es unknown
- 2008-04-18 UY UY31036A patent/UY31036A1/es not_active Application Discontinuation
-
2009
- 2009-10-06 US US12/573,961 patent/US7868007B2/en not_active Expired - Fee Related
- 2009-10-11 IL IL201416A patent/IL201416A0/en unknown
-
2010
- 2010-10-05 CY CY20101100884T patent/CY1111601T1/el unknown
- 2010-11-30 US US12/956,764 patent/US20110071161A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200906401A (en) | 2009-02-16 |
| CN101657451A (zh) | 2010-02-24 |
| IL201416A0 (en) | 2010-05-31 |
| DK2146991T3 (da) | 2010-11-22 |
| WO2008145842A2 (fr) | 2008-12-04 |
| FR2915197B1 (fr) | 2009-06-12 |
| ES2348969T3 (es) | 2010-12-17 |
| AU2008257323A1 (en) | 2008-12-04 |
| MX2009011215A (es) | 2009-11-02 |
| US7868007B2 (en) | 2011-01-11 |
| US20110071161A1 (en) | 2011-03-24 |
| EP2146991A2 (fr) | 2010-01-27 |
| SI2146991T1 (sl) | 2010-11-30 |
| CA2683933A1 (fr) | 2008-12-04 |
| JP2010524907A (ja) | 2010-07-22 |
| ATE475661T1 (de) | 2010-08-15 |
| DE602008001981D1 (de) | 2010-09-09 |
| CY1111601T1 (el) | 2015-10-07 |
| HRP20100573T1 (hr) | 2010-11-30 |
| RS51462B (sr) | 2011-04-30 |
| EP2146991B1 (fr) | 2010-07-28 |
| UY31036A1 (es) | 2008-11-28 |
| WO2008145842A3 (fr) | 2009-01-22 |
| US20100035893A1 (en) | 2010-02-11 |
| PL2146991T3 (pl) | 2011-01-31 |
| PT2146991E (pt) | 2010-10-04 |
| RU2009142430A (ru) | 2011-05-27 |
| KR20090130060A (ko) | 2009-12-17 |
| BRPI0810430A2 (pt) | 2014-10-14 |
| FR2915197A1 (fr) | 2008-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| AR075139A1 (es) | Compuestos biciclicos para la reduccion de la produccion de beta-amiloide | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CO6450621A2 (es) | Sulfonamidas nematocidas | |
| SV2006002110A (es) | Compuestos terapeuticos ref. pc32293a | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR068466A1 (es) | Cianoisoquinolina | |
| AR111682A1 (es) | Derivados de imidazopirimidina con sustituyentes fenilo y piridilo que contienen azufre | |
| AR065628A1 (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| PE20210478A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |